It was approved in 2018 for the treatment of X-linked hypophosphatemia and acts by blocking the function of fibroblast growth factor 23 (FGF23), increasing renal tubular phosphate reabsorption and normalizing serum phosphate levels [127]. Here, FGF23 is linked to X-linked hypophosphatemia.